Anixa Biosciences (ANIX) Change in Accured Expenses (2010 - 2025)

Anixa Biosciences (ANIX) has 16 years of Change in Accured Expenses data on file, last reported at $10000.0 in Q4 2025.

• Quarterly Change in Accured Expenses fell 96.27% year-over-year to $10000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was -$185000.0 (down 205.11% YoY) and the FY2025 annual result came in at -$185000.0, down 205.11% from the prior year.
• Change in Accured Expenses fell to $10000.0 in Q4 2025, from $185000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $528000.0 in Q4 2022 to a low of -$651000.0 in Q1 2023.
• A 5-year average of $42950.0 and a median of $122000.0 in 2021 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 1066.67% in 2022, down 3780.0% in 2022.
• Tracing ANIX's Change in Accured Expenses over 5 years: stood at $104000.0 in 2021, then soared by 407.69% to $528000.0 in 2022, then plunged by 89.02% to $58000.0 in 2023, then jumped by 362.07% to $268000.0 in 2024, then sank by 96.27% to $10000.0 in 2025.
• The last three Change in Accured Expenses figures came in at $10000.0 (Q4 2025), $185000.0 (Q3 2025), and $203000.0 (Q2 2025), per Business Quant data.